IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Balm)
NCT ID: NCT05171556
Last Updated: 2021-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
33 participants
OBSERVATIONAL
2021-04-20
2021-05-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is also to:
* evaluate the cutaneous sensitivity by a stinging test at D1 T0 and D22.
* evaluate the cutaneous sensitivity by a sensitive scale at D1 T0, D1 Timm\*, D8 and D22.
* evaluate the soothing efficacy by an efficacy questionnaire at D1 Timm\*, D8 and D22.
* evaluate the cosmetic acceptability by a questionnaire at D22.
This study is conducted as a national, monocentric, non-randomized open trial. The 33 subjects in this study (31 subjects on D22) present hypersensitive, reactive and intolerant skin on face. They are stinger subjects, with a dry to very dry skin.
Timm\*: 10 to 30 minutes after first application
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study includes 3 visits, including subjects' selection:
* V1: Baseline inclusion
* V2: 1 week, intermediate visit
* V3: 3 weeks, study end
The maximal study duration is 25 days.
The evaluation is at 3 times: D1 baseline, D8 at 1 week and D22 at 3 weeks of application of RV4942A - RY1985 with comparison of each time versus baseline.
There are twice-daily applications (morning and evening) of the test product on the face.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RV4942A arm
RV4942A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
Cosmetic product
RV4942A is a face balm product
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cosmetic product
RV4942A is a face balm product
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female aged between 18 and 65 years included
* Asian population (Chinese origin)
* Dry to very dry skin on the face
* Subject with phototype I to IV included
* Subject having signed his/her written informed consent for his/her participation in the study
* Subject who is currently not participating in another clinical study
* Subject affiliated to a social security system or health insurance, or is a beneficiary
* For woman of childbearing potential: use of an effective method of contraception and using it during the whole duration of the study
2. Criteria related to diseases and general health:
* Stinger subjects (evaluated by a stinger test)
* Subject with hypersensitive, reactive and intolerant skin on face
* Subject having a score superior to 4 on a sensitive scale for tightness parameter on the face
* Subject having a score superior to 4 on a sensitive scale for general discomfort parameter on the face
Exclusion Criteria
* For woman of childbearing potential: subject pregnant or breastfeeding or planning to be pregnant during the study
* Having a dermatological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Having an ophthalmological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Having personal medical history liable to interfere with the study data for the subject or incompatible with the study requirements
* Having history of abnormal reactions from exposure to sunlight
* Having taken any previous treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements
* Being under any treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements
* Subject who is not likely to be compliant with study-related requirements
* Subject deprived of freedom by administrative or legal decision or under guardianship
2. Criteria related to investigational product application areas:
* Having had any surgery, chemical or significant invasive dermotreatment on the experimental area considered by the Investigator liable to interfere with the study data, before the inclusion visit or foreseeing it for the duration of the study
* Having applied a skincare or make up product on the study areas the day of the inclusion visit. The usual cleanser is allowed
* Having received, on the study areas, artificial UV exposure or excessive exposure to natural sunlight within the 2 weeks before the inclusion visit (at Investigator's opinion)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lexi LIU
Role: STUDY_CHAIR
EUROFINS CHINA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins China
Guangzhou, Haizhu District, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RV4942A20200169
Identifier Type: -
Identifier Source: org_study_id